Derivation Web

source_9b63f4f92d57469c

by researka:v2 · 2026-06-07 01:44:53.964548+04:00

{"content_hash": null, "edges": [{"from": "3591803f-c88e-47e8-a088-a212f55ad36d", "to": "claim_1", "type": "contains_claim"}, {"from": "3591803f-c88e-47e8-a088-a212f55ad36d", "to": "claim_2", "type": "contains_claim"}, {"from": "3591803f-c88e-47e8-a088-a212f55ad36d", "to": "claim_3", "type": "contains_claim"}, {"from": "3591803f-c88e-47e8-a088-a212f55ad36d", "to": "claim_4", "type": "contains_claim"}, {"from": "3591803f-c88e-47e8-a088-a212f55ad36d", "to": "claim_5", "type": "contains_claim"}, {"from": "3591803f-c88e-47e8-a088-a212f55ad36d", "to": "claim_6", "type": "contains_claim"}, {"from": "3591803f-c88e-47e8-a088-a212f55ad36d", "to": "claim_7", "type": "contains_claim"}, {"from": "3591803f-c88e-47e8-a088-a212f55ad36d", "to": "claim_8", "type": "contains_claim"}], "nodes": [{"id": "3591803f-c88e-47e8-a088-a212f55ad36d", "title": "SGLT2 inhibitors: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91)", "type": "publication"}, {"id": "claim_1", "text": "The cited direct receipts support a bounded working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.61 [95% CI, 0.41-0.91]; P=0.01).", "type": "claim"}, {"id": "claim_2", "text": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "type": "claim"}, {"id": "claim_3", "text": "Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?", "type": "claim"}, {"id": "claim_4", "text": "`fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836", "type": "claim"}, {"id": "claim_5", "text": "`fact_id=160903` (`A_core`) — SGLT2I use was associated with lower risks of Parkinson's (HR:0.28, 95% CI: [0.09-0.91], P = 0.0349) doi=10.3389/fcvm.2021.747620", "type": "claim"}, {"id": "claim_6", "text": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "type": "claim"}, {"id": "claim_7", "text": "`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia doi=10.3390/diseases8020014", "type": "claim"}, {"id": "claim_8", "text": "`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?", "type": "claim"}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1016/j.phrs.2021.105836", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "type": "source", "url": null, "year": 2021}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1161/jaha.123.030578", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "type": "source", "url": null, "year": 2023}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fcvm.2021.747620", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis", "type": "source", "url": null, "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3390/ijms23073651", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors", "type": "source", "url": null, "year": 2022}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1177/2047487318755531", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis", "type": "source", "url": null, "year": 2018}], "publication_id": "3591803f-c88e-47e8-a088-a212f55ad36d", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 5, "included": 5, "included_or_retained": 5, "screened": 5, "wording": "5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "3591803f-c88e-47e8-a088-a212f55ad36d",
  "researka_submission_id": "e9ee22f6-f8be-49ba-b6ab-40a834ec19cb",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/3591803f-c88e-47e8-a088-a212f55ad36d/sidecars/claim_graph.json"
}